陕西省潼关县2013-2015年恶性肿瘤发病及死亡情况分析

Analysis of the incidence and mortality of malignant tumors from 2013 to 2015 in Tongguan County,Shaanxi Province

目的分析2013-2015年潼关县恶性肿瘤的发病及死亡情况,了解发病规律,为制订癌症防治及干预措施提供科学依据。方法收集肿瘤登记系统中2013-2015年潼关县恶性肿瘤发病资料,计算发病率、死亡率及构成比,并对资料进行统计分析。结果潼关县2013-2015年恶性肿瘤发病率基本保持稳定,各年发病率分别为164. 37/10万、161. 25/10万和168. 12/10万,死亡率从2013年的94. 97/10万上升到2015年的136. 84/10万,2013-2015年恶性肿瘤死亡率差异有统计学意义(χ2=12. 124,P <0. 01)。恶性肿瘤的发病率及死亡率在30岁后呈上升趋势,发病率于55～60岁达到高峰,死亡率于60～65岁达到高峰。胃、食管、支气管和肺、宫颈、肝和肝内胆管恶性肿瘤占潼关县恶性肿瘤发病率前5位,构成比为68. 03%。结论潼关县恶性肿瘤发病情况不容乐观,已经严重威胁着人群的健康,胃、食管、支气管和肺、宫颈、肝和肝内胆管恶性肿瘤应作为防治重点。

Objective To analyze the incidence and mortality of malignant tumors from 2013 to 201,to explore the morbidity laws of the malignancy,and to provide a scientific basis to make cancer prevention and intervention measures. Methods Data on the incidence of malignant tumors in Tongguan County from 2013 to 2015 in the cancer registration system were collected. The incidence,mortality and composition ratio were calculated,and the data were statistically analyzed. Results The incidence of malignant tumors in Tongguan County remained basically stable from 2013 to 2015. The annual incidence rates were 164. 37/100000,161. 25/100 000 and 168. 12/100 000 respectively. The mortality rate increased from 94. 97/100 000 in 2013 to 136. 84/100 000 in 2015. The difference in malignant tumor mortality between 2013 and 2015 was statistically significant.( χ2= 12. 124,P < 0. 01). The incidence and mortality of malignant tumors were on the rise after 30 years old. The incidence rate peaked at 55 ~60 years old,and the mortality rate peaked at 60 ~ 65 years old. Gastric,esophageal,bronchial and pulmonary,cervical,hepatic and intrahepatic bile duct malignancies accounted for the top 5 incidence of malignant tumors in Tongguan County,with a composition ratio of 68. 03%. Conclusion The incidence of malignant tumors in Tongguan is not optimistic,and it has seriously threatened the health of the population. The stomach,esophagus,bronchus and lung,cervical,liver and intrahepatic bile duct malignant tumors should be the focus of prevention and treatment.